Fundraising Fox
/Companies
Sign in

Noema Pharma

Founded 2019 · 35 employees on LinkedIn · 11 known investors

Find your way into Noema Pharma

Sign up to see every warm intro you have to Noema Pharma

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Noema Pharma team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs. The company works with patients, caregivers, and healthcare professionals throughout discovery and clinical development.

BiotechHealthtechMedical Devices

Founders & leadership

ILIlise Lombardo
Ilise LombardoChief Executive Officer
VKVolker Knappertz
Volker KnappertzExecutive Vice President of Research & DevelopmentBoard-certified neurologist with a medical degree from Cologne University and neurology training at Yale University and Wake Forest University. Knappertz held senior R&D and clinical roles at GW Pharmaceuticals (where he contributed to Epidiolex's global approvals), Aurinia Pharmaceuticals, Teva Pharmaceuticals, Bayer, AstraZeneca, and Medimmune before becoming Executive Vice President of Research & Development at Noema Pharma.
MSMichael Samar
Michael SamarChief Financial OfficerMichael Samar is Chief Financial Officer at Noema Pharma, a biopharmaceutical company developing oral small molecule therapeutics for neurological disorders. He has held executive finance roles overseeing capital raising, IPOs, mergers and acquisitions, and financial operations in the pharmaceutical and biotech sectors.
RLRob Lasser
Rob LasserChief Medical OfficerRob Lasser is a board-certified psychiatrist with an MD and MBA who has conducted clinical research in late-life depression and dementia while holding medical leadership roles at major pharmaceutical companies overseeing neuroscience development programs. He has maintained a clinical practice in geriatric psychiatry and psychopharmacology for nearly two decades and has published over 80 peer-reviewed articles in psychiatry and related fields.

Investors · 11

Jeito Capitallisted by Jeito CapitalParis

How we know: funding news · noemapharma.com · Not right? Tell us

Roche Venture Fundlisted by Roche Venture FundBasel · $648K – $3.2M

How we know: Roche Venture Fund's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Sofinnova Partnerslisted by Sofinnova PartnersParis · $540K – $27M

How we know: Sofinnova Partners's portfolio page · a partner's Signal profile · funding news · gildehealthcare.com · open dataset · 5k.vc investor directory · Not right? Tell us

EQTreportedNew York

How we know: funding news · s-ge.com · Not right? Tell us

EQT Life SciencesreportedAmsterdam · $11M – $66M

How we know: a partner's Signal profile · funding news · s-ge.com · Not right? Tell us

ForbionreportedNaarden

How we know: a partner's Signal profile · funding news · noemapharma.com · open dataset · 5k.vc investor directory · Not right? Tell us

Gilde HealthcarereportedUtrecht · $1.1M – $55M

How we know: funding news · gildehealthcare.com · Not right? Tell us

InvusreportedNew York

How we know: gildehealthcare.com · Not right? Tell us

Also in the syndicate · 2

Polaris PartnersUPMC Enterprises

Funding

SEC filings, press & company announcements

$112M disclosed across 1 of 3 rounds · 2023–2025

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 5

NMD PharmaNMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions. Its lead candidate, ignaseclant (NMD670), is in clinical development for Charcot-Marie-Tooth disease, generalized myasthenia gravis, and spinal muscular atrophy.</parameter> <parameter name="founders">[]
ForbionA venture capital firm investing in biotech companies across all stages of pharmaceutical development, and in sustainable solutions across food, agriculture, materials, and environmental technologies through its BioEconomy strategy.
DoximityDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
VeevaVeeva Clinical Platform is a cloud-based suite of connected applications for running clinical trials, covering clinical operations, clinical data, research sites, and patients. It serves biopharma sponsors, clinical research sites, and patients across trial management, data capture, and disclosures.
NrxpharmaNRx Pharmaceuticals develops medicines for people with unmet medical needs, focused on making untreatable diseases treatable. It operates in the pharmaceutical and biotech industry.

Companies working in the same space as Noema Pharma.

In the news

Noema Pharma Raises USD112M in Series B Financingfinsmes.com · Mar 2023Noema Pharma raises CHF 103 million (USD 112 million) in Series B financing round led by Forbion and Jeito Capital | Noema Pharmanoemapharma.com · Mar 2023

Frequently asked questions

What does Noema Pharma do?
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs. The company works with patients, caregivers, and healthcare professionals throughout discovery and clinical development.
Who are Noema Pharma's investors?
Noema Pharma's investors include BioMedPartners, Jeito Capital, Roche Venture Fund, Sofinnova Partners, EQT, EQT Life Sciences, Forbion, Gilde Healthcare and 1 more.
How much funding has Noema Pharma raised?
Noema Pharma has disclosed $112M raised across 1 of its 3 known rounds.